Supplementary Figure 1.



Interactions

Gene ID A	Gene name A	Gene ID B	Gene name B	Organism	Туре	Source	Score ? (/welcome/help#score)	
ENSG00000139180	NDUFA9 (/genes/649)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/3334
ENSG00000166477	LEO1 (/genes/540)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/2858
ENSG00000173692	PSMD1 (/genes/754)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/3644
ENSG00000164466	SFXN1 (/genes/830)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/3908
ENSG00000170222	ADPRM (/genes/30)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/82)
ENSG00000184110	EIF3C (/genes/322)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/1686
ENSG0000064313	TAF2 (/genes/867)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/3999
ENSG00000185085	INTS5 (/genes/492)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/2488
ENSG00000137038	TMEM261 (/genes/881)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/4031
ENSG00000133703	KRAS (/genes/7)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/2767
ENSG00000105835	NAMPT (/genes/642)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/3305
ENSG00000160752	FDPS (/genes/383)	ENSG0000082898	XPO1 (/genes/1061)	H. sapiens	SSL	BioGRID	1.0	View (/interactions/2038

slorth.biochem.sussex.ac.uk/interactions?utf8=/&gene=xpo1&organism=H.+sapiens&interaction_type=SSL&score_filter=1&commit=Search&disease... 1/2

XPO1-KRAS synthetic lethal interaction identified using the Slorth database (http://slorth.biochem.sussex.ac.uk/welcome/index)

Supplementary Figure 2.



KRAS WT, KRAS G12D and KRAS G12V MEF cell lines were refractory to growth inhibition by selinexor or MRTX1257 or their combinations. However, only KRAS4B G12C cells responded to KRAS G12C inhibitor MRTX1257.

Supplementary Figure 3.



Panc-1

CI For experimental valuesKPT330AMG510FaCI(nM)(nM)50200.16812272.761100400.2516872706.794200800.3351865.57e+004

KRAS G12D mutant PDAC cell line Panc-1 was refractory to growth inhibition by KRAS G12C inhibitor AMG510. Treatment of Panc-1 cells with combinations of selinexor and AMG510, did not show any synergistic effect (CI > 1).

Supplementary Figure 4.



Body Weights

Body weights of mice xenografted with MiaPaCa2 tumors were measured during the treatment period. Neither of the drugs, either as single agent or in combination, induced any loss of body weight.

Supplementary Table 1. Sequences of primers used

Primers		Sequences		
	Forward	GTGCAAGAGAGCTGAGGGAG		
KRAS	Reverse	ATGCTGGTGGGACAGAAGTG		
	Forward	GGAAAACTGTGAAACCCACCTT		
XPO1	Reverse	GCTGCATGGTCTGCTAACAT		
	Forward	ATTACGACCCGAGTGACGAG		
Erk2	Reverse	GATGTCTGAGCACGTCCAGT		
	Forward	TGAACTGGGGGAGGATTGTG		
BcI-2	Reverse	CGTACAGTTCCACAAAGGCA		
β-actin	Forward	GCACAGAGCCTCGCCTT		
	Reverse	TCATCATCCATGGTGAGCTG		
18S	Forward	GCAATTATTCCCCATGAACG		
	Reverse	GGCCTCACTAAACCATCCAA		

Supplementary Table 2. Combination Index (CI) values at various dose combinations of the drugs tested on different KRAS G12C mutant cell lines (MiaPaCa-2, NCI-H2122 and KRAS4B G12C)

	MiaPaCa-2		
Selinexor (nM)	AMG510 (nM)	CI	
50	20	0.927	
100	40	1.162	
200	80	1.554	
	NCI-H2122		
Selinexor (nM)	AMG510 (nM)	CI	
150	50	0.986	
300	100	0.931	
600	200	0.781	
	KRAS4B G12C		
Selinexor (nM)	MRTX1257 (nM)	CI	
200	50	0.41	
400	100	0.451	
800	200	0.627	
	KRAS4B G12C		
Selinexor (nM)	AMG510 (nM)	CI	
800	800	0.103	